Watson’s Clarithromycin extended-release product is the generic equivalent to Abbott’s Biaxin XL, which is indicated to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
The FDA granted final approval of Watson’s abbreviated new drug application (ANDA) for Clarithromycin extended-release on June 24, 2004. Patent infringement litigation related to Watson’s ANDA was dismissed with prejudice on July 12, 2007.